Spero Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new investor Pfizer Inc. for private placement of 2,362,348 common shares $16.93 per share for gross proceeds of $39,994,551.64 on June 30, 2021. The company has raised funding as part of the Pfizer Breakthrough Growth Initiative. The company received funding from 1 investor pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -0.70% | -1.39% | -3.40% |
05-15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
05-15 | Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 77.2M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.